HCG 2500 IU

DRAGON PHARMA HCG 2500 IU

Dragon Pharma HCG 2500 IU represents the optimal choice for precise testicular maintenance and fertility support for athletes, bodybuilders, and men seeking targeted hormonal management in the United States. This mid-strength formulation offers the perfect balance between convenience and dosing flexibility, containing 2500 International Units (IU) of highly purified Human Chorionic Gonadotropin derived from advanced recombinant DNA technology. Each 2 mL vial provides sufficient HCG for 2.5-10 weeks of treatment depending on protocol, making it ideal for those preferring smaller, more frequently reconstituted batches to ensure maximum peptide freshness. Third-party laboratory testing confirms exceptional potency at 2976 IU per vial—exceeding the labeled 2500 IU by 19%—demonstrating Dragon Pharma's commitment to quality that surpasses industry standards. The 2500 IU strength is particularly suited for lower-dose maintenance protocols, shorter treatment durations, and users who value precise dosing without concerns about peptide stability during extended post-reconstitution use.

DRUG COMPOSITION

Each vial contains 2500 International Units (IU) of Human Chorionic Gonadotropin as a lyophilized white powder. HCG is a glycoprotein hormone composed of 244 amino acids with a molecular weight of approximately 36.7 kDa, featuring an alpha subunit (92 amino acids) identical to LH, FSH, and TSH, and a unique beta subunit (145 amino acids) that confers biological specificity. Dragon Pharma utilizes recombinant DNA technology for HCG production, ensuring superior purity, batch consistency, and reduced immunogenicity compared to traditional urinary-derived preparations. The product contains minimal stabilizers (typically human serum albumin or amino acids) to maintain structural integrity during lyophilization but is free from unnecessary excipients or preservatives that could interfere with biological activity. The lyophilization process preserves the delicate tertiary structure essential for optimal receptor binding and signal transduction while providing extended shelf life and stability during shipping and storage.

PHARMACEUTICAL FORM

Sterile lyophilized powder for injection in a 2 mL glass vial sealed with a rubber stopper and silver aluminum cap. The lyophilized form offers superior stability compared to pre-mixed liquid preparations, with extended shelf life and reduced risk of microbial contamination or glycoprotein degradation. The powder reconstitutes rapidly with bacteriostatic water or sterile saline, forming a clear solution suitable for subcutaneous or intramuscular injection. Each vial is individually packaged with tamper-evident seals and includes batch-specific quality control documentation verifying biological activity. The 2 mL volume allows for flexible reconstitution—typically with 1-2.5 mL of diluent to achieve concentrations ideal for precise low-dose administration using insulin syringes. Special handling instructions emphasize gentle swirling rather than vigorous shaking to maintain glycoprotein integrity, with visual confirmation of complete dissolution before administration.

PHARMACEUTICAL GROUP AND ATC CODE

HCG belongs to the therapeutic category of gonadotropins (ATC code: G03GA). According to the WHO Anatomical Therapeutic Chemical Classification System, it falls under gonadotropins and other ovulation stimulants. In reproductive endocrinology, it's classified as a luteinizing hormone (LH) analog due to structural and functional similarities, specifically binding to the luteinizing hormone/choriogonadotropin receptor (LHCGR). For male therapeutic applications, it's categorized as a Leydig cell stimulant that promotes endogenous testosterone production and provides spermatogenesis support. The 2500 IU strength is particularly suited for maintenance protocols where consistent low-dose stimulation is preferred over periodic high-dose administration, allowing for more physiological mimicking of natural LH pulsatility while minimizing receptor desensitization risks.

PHARMACOLOGICAL PROPERTIES

HCG exerts its primary effects through high-affinity binding to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on Leydig cells in the testes, stimulating testosterone biosynthesis and supporting the spermatogenic microenvironment. According to research published in the Journal of Andrology, HCG maintains testicular steroidogenesis and partially preserves spermatogenesis during exogenous androgen administration by providing LH-like activity that bypasses hypothalamic-pituitary suppression. The hormone exhibits a plasma half-life of 24-36 hours (compared to 20-30 minutes for endogenous LH) due to sialic acid residues that reduce hepatic clearance, allowing sustained testicular stimulation with twice-weekly administration. HCG also demonstrates weak cross-reactivity with thyroid-stimulating hormone (TSH) receptors due to structural homology, though clinically significant thyroid stimulation is rare at therapeutic doses. Unlike direct testosterone administration which suppresses endogenous production via negative feedback, HCG stimulates natural testicular function while providing therapeutic androgen support—a crucial distinction for fertility preservation and post-cycle recovery.

THERAPEUTICAL INDICATIONS

Dragon Pharma HCG 2500 IU is specifically indicated for: low-dose testicular maintenance during anabolic steroid cycles (250-500 IU protocols), precise fertility support with minimized estrogen conversion risk, shorter-duration post-cycle therapy (PCT) protocols, initial HCG response assessment in new users, combination protocols with other fertility medications, testosterone replacement therapy (TRT) adjunct for testicular preservation, hypogonadotropic hypogonadism management with dose titration, and protocols requiring frequent reconstitution for maximum peptide freshness. The 2500 IU strength is particularly valuable for bodybuilders using moderate-dose cycles, men sensitive to estrogen side effects who benefit from lower per-dose administration, those with shorter cycle durations (8-12 weeks), and users who prefer to reconstitute fresh batches more frequently rather than using larger vials over extended periods.

DOSES AND METHOD OF ADMINISTRATION

Reconstitute the 2500 IU vial with 1-2.5 mL of bacteriostatic water, gently swirling until completely dissolved. Standard dosing protocols: For testicular maintenance during cycles: 250-500 IU administered subcutaneously every 3.5 days (Monday/Thursday or Tuesday/Friday). For PCT initiation: 500-1000 IU every other day for 10-14 days. For fertility support: 500-1500 IU every other day (under appropriate supervision). For TRT adjunct: 250-350 IU twice weekly. For hypogonadism: 500-1000 IU 2-3 times weekly. Administration is typically subcutaneous in abdominal or thigh adipose tissue using insulin syringes for precise measurement, though intramuscular injection in gluteal or deltoid muscles is also effective. The 2500 IU vial provides 5-10 doses at typical maintenance levels, allowing for 2.5-5 weeks of treatment without reconstituted solution exceeding optimal stability periods. Always begin at the lower end of dosing ranges to assess individual response and estrogen conversion tendency before increasing.

CYCLE/STACKING

The 2500 IU HCG strength integrates perfectly with various compounds for optimized hormonal management. Combine with Femara for potent aromatase inhibition to manage estrogen conversion from HCG-stimulated testosterone. Stack with Clomid during PCT for comprehensive HPTA recovery combining testicular stimulation (HCG) and hypothalamic-pituitary modulation (SERM). For enhanced fertility outcomes, add HMG 150 IU to provide both LH (via HCG) and FSH activity for complete spermatogenesis restoration. During testosterone cycles, include Masteron 100 to provide additional androgenic effects while maintaining testicular function with HCG. For those concerned about prolactin management, consider Caber alongside HCG if symptoms of prolactin elevation emerge during treatment.

POST CYCLE THERAPY

The 2500 IU HCG formulation is exceptionally well-suited for post-cycle therapy due to its ideal dosing size for typical PCT durations. The standard PCT protocol involves administering 500-1000 IU every other day for 14-21 days at the beginning of recovery, providing 5-10 doses from a single vial—perfect for a 2-3 week "HCG blast" before transitioning to SERMs alone. This approach jumpstarts testicular testosterone production while the hypothalamic-pituitary axis recovers from suppression, with the 2500 IU size minimizing waste and ensuring fresh reconstitution for the entire PCT period. For cycles of moderate duration and suppression (8-16 weeks), one vial is often sufficient for the entire HCG phase of PCT. The smaller vial size also allows for easier dose titration if estrogen side effects become problematic during the sensitive PCT period. Many users prefer the 2500 IU strength for PCT specifically because it aligns perfectly with typical treatment durations without requiring extended storage of reconstituted peptide.

SIDE EFFECTS

Common side effects at typical 2500 IU-protocol doses include mild gynecomastia symptoms (nipple tenderness, puffiness) due to increased testosterone aromatization to estrogen, transient fluid retention, minor acne flare-ups in predisposed individuals, occasional headache or fatigue, and injection site reactions (redness, itching, discomfort). The lower per-dose administration possible with 2500 IU vials often reduces side effect severity compared to higher-dose protocols. Less common but serious effects include ovarian hyperstimulation syndrome (OHSS) symptoms even in men (abdominal discomfort, nausea, swelling), allergic reactions to protein components, and theoretical thrombotic risk with significant estrogen elevation. Unlike exogenous testosterone, HCG doesn't typically cause erythrocytosis, significant lipid profile alterations, or hepatotoxicity. Most side effects are dose-dependent and manageable with dosage adjustments, concomitant aromatase inhibitor use, or proper timing relative to PCT phases.

CONTRAINDICATIONS

Contraindications include known hypersensitivity to HCG, human gonadotropins, or any component of the formulation. Not recommended for individuals with hormone-sensitive malignancies (prostate, breast, testicular cancer) unless under specialized oncological supervision. Those with untreated thyroid or adrenal insufficiency should have these conditions addressed before HCG initiation. Men with primary testicular failure (primary hypogonadism) will not respond meaningfully to HCG stimulation. Not for use in women who are pregnant, attempting conception, or could become pregnant due to potential teratogenic effects. Individuals with severe renal impairment (eGFR <30 mL/min) or hepatic dysfunction should consult a healthcare provider before use. Prepubertal boys should only use for specific medical indications (cryptorchidism) with careful monitoring to prevent premature epiphyseal closure. History of thromboembolic disorders requires careful risk-benefit assessment.

OVERDOSE

Acute overdose with 2500 IU HCG typically manifests as exaggerated hormonal effects: significant gynecomastia development, pronounced fluid retention and bloating, emotional lability or mood disturbances, headache, and in extreme cases, symptoms resembling ovarian hyperstimulation syndrome (OHSS) even in males (abdominal distension, discomfort, nausea). In cases of significant overdose, discontinue use and implement supportive measures: apply cold compresses to breast tissue for gynecomastia discomfort, monitor fluid balance, consider short-term aromatase inhibitor administration, and provide symptomatic relief as needed. No specific antidotes exist, but symptoms typically resolve as the hormone clears from circulation (3-5 days for acute effects, longer for tissue changes like gynecomastia). The 2500 IU vial size provides some inherent overdose protection compared to larger vials, as total available hormone is limited. However, repeated administration of inappropriately high doses can still lead to cumulative effects requiring several weeks for complete resolution.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

Employ strict aseptic technique during reconstitution and injection to prevent microbial contamination or infection. Rotate subcutaneous injection sites systematically to prevent lipohypertrophy or tissue irritation. Monitor closely for signs of excessive estrogen conversion (nipple tenderness, emotional changes, fluid retention) and implement aromatase inhibitor therapy promptly if needed. Regular blood testing for testosterone, estradiol, LH, and FSH is recommended during extended use to guide dosing adjustments. Consider semen analysis if fertility is a primary treatment goal. Discontinue immediately if signs of severe allergic reaction occur (urticaria, angioedema, respiratory distress). Those with seizure disorders should use cautiously due to potential androgen-mediated effects on seizure threshold. Store reconstituted solution refrigerated at 2-8°C and use within 30 days. Avoid concurrent use with other potent gonadotropin stimulants unless under specialist supervision. Men over 50 should have baseline and periodic PSA monitoring when using HCG.

INTERACTIONS WITH OTHER DRUGS

HCG may potentiate effects of other gonadotropins and androgenic medications. Aromatase inhibitors (Femara, Aromasin) are frequently co-administered to manage estrogen conversion. Dopamine agonists (Caber) may be indicated if prolactin elevation occurs (though HCG has minimal direct prolactin effect). Glucocorticoids may reduce HCG effectiveness through unclear mechanisms. Concurrent exogenous testosterone administration may diminish HCG's testicular stimulation due to combined negative feedback on the HPTA axis. Herbal supplements with estrogenic activity (soy isoflavones, red clover) may exacerbate estrogen-related side effects. Always disclose all medications, supplements, and herbal products to healthcare providers when using HCG. Those using anticoagulant therapy require closer monitoring due to potential hormonal effects on coagulation parameters. Antiepileptic drugs that induce hepatic enzymes may accelerate HCG metabolism.

PRESENTATION, PACKAGING

Dragon Pharma HCG 2500 IU is presented in sterile 2 mL glass vials with gray rubber stoppers and silver aluminum seals. Each vial contains 2500 IU of lyophilized Human Chorionic Gonadotropin. Product is available in packs of 1, 3, or 6 vials, often with bacteriostatic water vials included for convenient reconstitution. Each vial is individually labeled with product name, strength (2500 IU/vial), batch number, expiration date, and unique serial number for authenticity verification and quality tracking. Packaging features tamper-evident components and discreet outer materials for privacy. Complete instructions for proper reconstitution technique (emphasizing gentle swirling), storage conditions, and administration methods are included. The silver color coding distinguishes the 2500 IU strength from other Dragon Pharma HCG formulations for easy identification. Larger pack sizes may include insulin syringes and alcohol swabs for complete treatment convenience.

STORAGE

Store unopened vials at 2-8°C (36-46°F) in refrigerator. Avoid freezing. Protect from light exposure. After reconstitution with bacteriostatic water, store at 2-8°C (36-46°F) and use within 30 days. Do not use if solution appears cloudy, discolored, or contains particulate matter. Avoid temperature fluctuations and repeated freeze-thaw cycles. For travel, use insulated containers with cold packs. Long-term storage (beyond 6 months) should maintain consistent refrigeration. Shelf life of unopened vials is 24 months from manufacturing date when stored properly. Keep out of reach of children and pets. Do not use beyond expiration date printed on vial. Note that potency may gradually decline after reconstitution even with proper refrigeration, so consistent use within the 30-day window is recommended.

DELIVERY TO THE USA

All shipments to the United States are dispatched discreetly with guaranteed temperature-controlled delivery. We employ specialized cold-chain logistics with temperature monitoring devices to ensure hormone integrity throughout transit. Most orders arrive within 7-10 business days with comprehensive tracking and temperature verification data provided. Packaging is plain, unmarked, and includes insulated containers with appropriate cold packs for optimal temperature maintenance. We offer reshipment guarantee for orders lost during transit or compromised by temperature excursions. Express shipping options (3-5 business days) with enhanced cold-chain protection are available. All packages require signature confirmation upon delivery. Domestic reshipping services provide additional privacy protection for concerned customers. International shipping follows all applicable regulations with appropriate documentation.

LEGAL STATUS

In the United States, HCG is classified as a prescription medication under the Food, Drug, and Cosmetic Act and is designated as a Schedule III controlled substance when intended for weight loss applications. It is unlawful to purchase, possess, or distribute without a valid prescription from a licensed healthcare provider. However, for legitimate research purposes by qualified institutions, it may be obtained through appropriate channels. This product is sold exclusively for laboratory research applications. Not for human consumption, diagnosis, or treatment of any medical condition. Purchasers assume full responsibility for compliance with all applicable local, state, and federal regulations. In athletic competitions, most governing bodies permit therapeutic use with appropriate medical documentation. Always consult with qualified legal counsel regarding specific jurisdictional status before acquisition.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• National Institutes of Health - HCG in Male Reproductive Health

PROFILE

• Chemical name: Human Chorionic Gonadotropin
• Molecular weight: 36.7 kDa (approximately)
• Chemical structure: Glycoprotein with alpha (92 aa) and beta (145 aa) subunits
• Percentage of anabolic activity: Indirect via testosterone stimulation
• Percentage of androgenic activity: 0% (not directly androgenic)
• Active half life: 24-36 hours (subcutaneous/intramuscular administration)
• Recommended dosage: 250-1000 IU 2-3 times weekly
• Acne: Possible secondary to increased testosterone
• Bloating (water retention): Common via estrogen conversion pathway
• HBR (Hepatobiliary-related): No direct hepatotoxicity documented
• Hepatic toxicity: None reported at therapeutic doses
• Aromatization: Does not aromatize directly but stimulates testosterone which may
• Detection time: 5-7 days in standard drug screens
• Anabolic/Androgenic Ratio: N/A (not an anabolic steroid)
• Primary receptor: Luteinizing hormone/choriogonadotropin receptor (LHCGR)
• Amino acid composition: 244 amino acids total
• Production method: Recombinant DNA technology (superior purity)
• Biological standardization: 2976 IU actual potency per vial (exceeds label)

Third Party Lab Test

2023-09-28

View Result

2976 IU